Skip to content
Assyro AI
Orange Book drug · Brand (NDA)

Aponvie

Aprepitant

RLDNDA 216457 Heron Theraps Inc
Approved
Sep 16, 2022
Strengths
1
Listed patents
14

What does the FDA Orange Book show for Aponvie?

Aponvie contains Aprepitant and is the new drug FDA Orange Book record for NDA 216457. The application has 1 presentation with strength, dosage-form, route, status, RLD/RS, TE, patent, and exclusivity context. Current inventory and clinical labeling are not established without an application-matched source.

FDA application
NDA 216457

New drug application identity from the Orange Book snapshot.

Application holder
Heron Therapeutics Inc

The listed applicant holds the FDA application; this field does not establish the product manufacturer.

Product presentations
1

Each FDA product number remains tied to its own strength, dosage form, route, and status.

Marketing categories
Prescription

Orange Book marketing categories do not establish real-time inventory or commercial availability.

Reference roles
RLD / RS

RLD and RS designations are presentation-specific, not inferred from the trade name.

TE codes
None posted

Therapeutic-equivalence codes apply only within the matching Orange Book product heading.

Listed patents
14

A zero means none appear in this snapshot, not that no patent rights exist.

Exclusivity records
0

FDA exclusivity and listed patent protection are distinct regulatory concepts.

Sourced from the official FDA Orange Book data file · snapshot refreshed

FDA product-presentation matrix

Every product number in this exact application
Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
ProductStrengthDosage form / routeMarketing statusTE codeReference role
00132MG/4.4ML (7.2MG/ML)EMULSIONINTRAVENOUSPrescriptionNone posted
RLDRS

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Heron Therapeutics Inc

The Orange Book identifies this organization as the applicant responsible for NDA 216457.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not
FDA marketing status

1 presentation listed as prescription

RX and OTC are Orange Book marketing categories, not real-time inventory signals. Confirm current commercial availability with labeling, the application holder, or an authoritative drug listing.

Therapeutic equivalence

No TE code is posted for this application

No TE code does not mean FDA found the product ineffective or non-equivalent. FDA generally publishes TE evaluations for multisource prescription products; single-source and some other products may have no code.

Patent & exclusivity record

14 listed patent expirations and 0 exclusivity dates remain on or after Jul 26, 2026

The latest future date recorded across those files is Sep 18, 2035. Patent and FDA exclusivity operate independently, can overlap, and do not by themselves predict a generic launch date.

Same-ingredient landscape

4 other ANDAs and 3 other NDAs found

3 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

NDA 216457 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Why are clinical sections unavailable?

Exact application-label matching status
Exact source match queuedQueue NDA-216457

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Product detail

NDA 216457
RLDRS
Strength
32MG/4.4ML (7.2MG/ML)
Dosage form
EMULSION
Route
INTRAVENOUS
Marketing status
Prescription

Key dates

Approval, patents, exclusivity

  1. Approval

    FDA approval date of this drug product.

    3 yr 11 mo ago

  2. Today

  3. Patent 10500208 expires

    Listed drug product patent expiration.

    in 9 yr 3 mo

  4. Patent 10624850 expires

    Listed method-of-use patent (U-3440) expiration.

    in 9 yr 3 mo

  5. Patent 10953018 expires

    Listed method-of-use patent (U-3440) expiration.

    in 9 yr 3 mo

  6. Patent 11173118 expires

    Listed drug product patent expiration.

    in 9 yr 3 mo

  7. Patent 11744800 expires

    Listed drug product patent expiration.

    in 9 yr 3 mo

  8. Patent 11878074 expires

    Listed method-of-use patent (U-3787) expiration.

    in 9 yr 3 mo

  9. Patent 12115254 expires

    Listed drug product patent expiration.

    in 9 yr 3 mo

  10. Patent 12115255 expires

    Listed drug product patent expiration.

    in 9 yr 3 mo

  11. Patent 12290520 expires

    Listed drug product patent expiration.

    in 9 yr 3 mo

  12. Patent 9561229 expires

    Listed drug product patent expiration.

    in 9 yr 3 mo

  13. Patent 9808465 expires

    Listed method-of-use patent (U-3440) expiration.

    in 9 yr 3 mo

  14. Patent 9974742 expires

    Listed drug product patent expiration.

    in 9 yr 3 mo

  15. Patent 9974793 expires

    Listed drug product patent expiration.

    in 9 yr 3 mo

  16. Patent 9974794 expires

    Listed drug product patent expiration.

    in 9 yr 3 mo

Patent & exclusivity timeline

Protection horizon
20262027202820292030203120322033203420352036TodayPatent 10500208: 2035-09-18Patent 10500208Patent 10624850: 2035-09-18Patent 10624850Patent 10953018: 2035-09-18Patent 10953018Patent 11173118: 2035-09-18Patent 11173118Patent 11744800: 2035-09-18Patent 11744800Patent 11878074: 2035-09-18Patent 11878074Patent 12115254: 2035-09-18Patent 12115254Patent 12115255: 2035-09-18Patent 12115255Patent 12290520: 2035-09-18Patent 12290520Patent 9561229: 2035-09-18Patent 9561229Patent 9808465: 2035-09-18Patent 9808465Patent 9974742: 2035-09-18Patent 9974742Patent 9974793: 2035-09-18Patent 9974793Patent 9974794: 2035-09-18Patent 9974794
Patent expiryExclusivity endToday

Pharmaceutical detail

FDA product record

Active ingredient

APREPITANT

Strength

32MG/4.4ML (7.2MG/ML)

Dosage form

EMULSION

Route

INTRAVENOUS

TE code

Not listed

Application

NDA 216457

Product number

001

Marketing status

Prescription

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10500208in 9 yr 3 mo
Product
10624850in 9 yr 3 mo
U-3440
10953018in 9 yr 3 mo
U-3440
11173118in 9 yr 3 mo
Product
11744800in 9 yr 3 mo
ProductU-3690
11878074in 9 yr 3 mo
U-3787
12115254in 9 yr 3 mo
Product
12115255in 9 yr 3 mo
Product
12290520in 9 yr 3 mo
Product
9561229in 9 yr 3 mo
ProductU-3440
9808465in 9 yr 3 mo
U-3440
9974742in 9 yr 3 mo
Product
9974793in 9 yr 3 mo
Product
9974794in 9 yr 3 mo
ProductU-3440

Active-ingredient family

Brand + generics

This is a reference-listed drug (RLD), the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

View full Aprepitant family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

  • The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
  • RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
  • Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
  • Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
  • The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.

Aponvie: frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.

Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of NDA 216457 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo